ROCKVILLE, Md.--(BUSINESS WIRE)--BioMarker Strategies, LLC, today announced that the Chinese Patent Office has granted a patent covering the Company’s PathMAP® Functional Signaling Profile technology. The announcement was made today at the BIO International Convention, which is back in Boston, Massachusetts to celebrate history-making innovation.
“PathMAP Functional Signaling Profiles are made possible by our proprietary SnapPath Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers,” said Jerry Parrott, President and CEO, BioMarker Strategies. “PathMAP Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells.”
The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs in development for treatment of solid tumor cancers. The BioMarker Strategies business model is focused on using its proprietary ex vivo technology to provide research services to companies developing targeted drugs and combinations for the treatment of patients with these cancers.
“Our Company was founded to address the reality that available biomarker tests for solid tumors primarily rely on dead, fixed tissue samples,” Mr. Parrott said. “Tests based on such static samples can identify mutations and suggest general therapeutic approach, but are not generally useful in identifying or understanding mechanisms of acquired resistance, and do not accurately and dependably predict individual tumor response to treatment.”
|
Patents Granted BioMarker Strategies for the SnapPath® Cancer Diagnostics System: |
||||||
|
“Improved Methods and Devices for Cellular Analysis” |
||||||
|
Country/Region |
Patent # |
Issue Date |
Expiration |
|||
| United States | US9121801 | September 1, 2015 | December 28, 2030 | |||
| Europe | EP2210080 | January 28, 2015 | October 24, 2028 | |||
| Australia | AU2008317329 | January 15, 2015 | October 24, 2028 | |||
| Australia | AU2014277688 | January 19, 2017 | October 24, 2028 | |||
| Canada | CA2703631 | August 22, 2017 | October 24, 2028 | |||
| Hong Kong | HK1145878 | August 14, 2015 | October 24, 2028 | |||
| Japan | JP6177841 | July 21, 2017 | October 24, 2028 | |||
| Korea | KR10-1658245 | September 9, 2016 | October 24, 2028 | |||
|
Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology: |
||||||
|
“Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression” |
||||||
|
Country/Region |
Patent # |
Issue Date |
Expiration |
|||
| United States | US9766249 | September 19, 2017 | August 31, 2025 | |||
| Europe | EP2561368 | August 2, 2017 | April 18, 2031 | |||
| Australia | AU2011242990 | May 28, 2015 | April 18, 2031 | |||
| Canada | CA2795362 | March 20, 2018 | April 18, 2031 | |||
| China | ZL201180030332.9 | April 13, 2018 | April 18, 2031 | |||
| Japan | JP6158078 | June 16, 2017 | April 18, 2031 | |||
| Singapore | SG184507 | May 6, 2015 | April 18, 2031 | |||
About BioMarker Strategies
BioMarker Strategies developed the SnapPath Cancer Diagnostics System. SnapPath is an automated and highly customizable fluidics-based system consisting of a compact bench-top instrument and a single-use cartridge for required consumables and reagents. The SnapPath System generates purified populations of live solid tumor cells from fresh biopsies or other fresh tissue samples such as xenografts or tumorgrafts, and keeps them alive on the instrument to enable generation of the highly predictive PathMAP Functional Signaling Profiles.
The capabilities of SnapPath and the Functional Signaling Profiles it enables are available for use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.
Forward-Looking Statements
The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.
